SG10201809428UA - Insulin receptor partial agonists - Google Patents

Insulin receptor partial agonists

Info

Publication number
SG10201809428UA
SG10201809428UA SG10201809428UA SG10201809428UA SG10201809428UA SG 10201809428U A SG10201809428U A SG 10201809428UA SG 10201809428U A SG10201809428U A SG 10201809428UA SG 10201809428U A SG10201809428U A SG 10201809428UA SG 10201809428U A SG10201809428U A SG 10201809428UA
Authority
SG
Singapore
Prior art keywords
partial agonists
insulin receptor
receptor partial
insulin
dimers
Prior art date
Application number
SG10201809428UA
Other languages
English (en)
Inventor
Songnian Lin
Lin Yan
Pei Huo
Dmitri Pissarnitski
Danqing Feng
Ravi Nargund
Yuping Zhu
Ahmet Kekec
Christina Madsen-Duggan
Zhi-Cai Shi
Zhicai Wu
Yingjun Mu
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of SG10201809428UA publication Critical patent/SG10201809428UA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
SG10201809428UA 2014-11-21 2015-11-19 Insulin receptor partial agonists SG10201809428UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462082857P 2014-11-21 2014-11-21
US201562242503P 2015-10-16 2015-10-16

Publications (1)

Publication Number Publication Date
SG10201809428UA true SG10201809428UA (en) 2018-11-29

Family

ID=54838417

Family Applications (4)

Application Number Title Priority Date Filing Date
SG10201809428UA SG10201809428UA (en) 2014-11-21 2015-11-19 Insulin receptor partial agonists
SG10201809427SA SG10201809427SA (en) 2014-11-21 2015-11-19 Insulin receptor partial agonists
SG10201809457YA SG10201809457YA (en) 2014-11-21 2015-11-19 Insulin receptor partial agonists
SG11201704064TA SG11201704064TA (en) 2014-11-21 2015-11-19 Insulin receptor partial agonists

Family Applications After (3)

Application Number Title Priority Date Filing Date
SG10201809427SA SG10201809427SA (en) 2014-11-21 2015-11-19 Insulin receptor partial agonists
SG10201809457YA SG10201809457YA (en) 2014-11-21 2015-11-19 Insulin receptor partial agonists
SG11201704064TA SG11201704064TA (en) 2014-11-21 2015-11-19 Insulin receptor partial agonists

Country Status (27)

Country Link
US (4) US10017556B2 (es)
EP (4) EP3660040A3 (es)
JP (5) JP6484337B2 (es)
KR (2) KR102049647B1 (es)
CN (2) CN108064173B (es)
AR (1) AR102712A1 (es)
AU (3) AU2015349890B2 (es)
BR (2) BR122024000903A2 (es)
CA (2) CA2966765C (es)
CL (3) CL2017001288A1 (es)
CO (1) CO2017004976A2 (es)
CR (1) CR20170208A (es)
DO (1) DOP2017000124A (es)
EA (1) EA036714B1 (es)
ES (1) ES2946247T3 (es)
GT (1) GT201700104A (es)
IL (1) IL252257A0 (es)
MX (3) MX2017006651A (es)
NI (1) NI201700060A (es)
PE (1) PE20170957A1 (es)
PH (1) PH12017500935A1 (es)
SG (4) SG10201809428UA (es)
SV (1) SV2017005445A (es)
TN (1) TN2017000178A1 (es)
TW (1) TW201625673A (es)
WO (1) WO2016081670A2 (es)
ZA (1) ZA201703238B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016020288A1 (en) 2014-08-04 2016-02-11 Nuevolution A/S Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases
JP6484337B2 (ja) * 2014-11-21 2019-03-13 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． インスリン受容体部分アゴニスト
AR105616A1 (es) 2015-05-07 2017-10-25 Lilly Co Eli Proteínas de fusión
EP3463429A4 (en) * 2016-05-24 2020-07-22 Merck Sharp & Dohme Corp. PARTIAL INSULIN RECEPTOR AGONISTS AND GLP-1 ANALOGUES
US10689430B2 (en) 2016-05-25 2020-06-23 Merck Sharp & Dohme Corp. Insulin receptor partial agonists
CN109891237B (zh) * 2016-10-24 2022-08-23 诺和诺德股份有限公司 胰岛素制剂的生物测定法
MX2020001434A (es) 2017-08-17 2020-03-20 Novo Nordisk As Analogos de insulina acilados novedosos y usos de estos.
US12018087B2 (en) 2018-08-02 2024-06-25 Dyne Therapeutics, Inc. Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
US11168141B2 (en) 2018-08-02 2021-11-09 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
AU2019312692A1 (en) 2018-08-02 2021-03-11 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
AU2019316103A1 (en) 2018-08-02 2021-03-11 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
US11911484B2 (en) 2018-08-02 2024-02-27 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
CN112898172B (zh) * 2019-12-04 2022-05-31 中国科学院大连化学物理研究所 可被羧肽酶酶解的双亲和功能团化合物的合成方法
EP4076657A1 (en) 2019-12-20 2022-10-26 Nuevolution A/S Compounds active towards nuclear receptors
CA3174176A1 (en) 2020-03-31 2021-10-07 Sanne Schroder Glad Compounds active towards nuclear receptors
MX2022012260A (es) 2020-03-31 2022-11-30 Nuevolution As Compuestos activos frente a receptores nucleares.
KR20230079068A (ko) * 2020-09-03 2023-06-05 다인 세라퓨틱스, 인크. 단백질-올리고뉴클레오티드 복합체의 제조 방법
WO2022055877A2 (en) * 2020-09-09 2022-03-17 Merck Sharp & Dohme Corp. Insulin receptor partial agonists
US11633498B2 (en) 2021-07-09 2023-04-25 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US11969475B2 (en) 2021-07-09 2024-04-30 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
US11771776B2 (en) 2021-07-09 2023-10-03 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US11648318B2 (en) 2021-07-09 2023-05-16 Dyne Therapeutics, Inc. Anti-transferrin receptor (TFR) antibody and uses thereof
US11638761B2 (en) 2021-07-09 2023-05-02 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy
US11931421B2 (en) 2022-04-15 2024-03-19 Dyne Therapeutics, Inc. Muscle targeting complexes and formulations for treating myotonic dystrophy

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1381273A (en) * 1971-01-28 1975-01-22 Nat Res Dev Insulin derivatives
US3907763A (en) 1972-03-01 1975-09-23 Bayer Ag Insulin derivatives crosslinked by a dicarboxylic acid moiety
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
US5514646A (en) 1989-02-09 1996-05-07 Chance; Ronald E. Insulin analogs modified at position 29 of the B chain
US5304473A (en) 1991-06-11 1994-04-19 Eli Lilly And Company A-C-B proinsulin, method of manufacturing and using same, and intermediates in insulin production
WO1995016708A1 (en) 1993-12-17 1995-06-22 Novo Nordisk A/S Proinsulin-like compounds
CA2223272A1 (en) 1995-05-05 1996-11-07 Ronald Eugene Chance Single chain insulin with high bioactivity
JP2002517437A (ja) * 1998-06-08 2002-06-18 アドバンスド メディスン インコーポレーテッド 新規なナトリウムチャンネル薬剤および使用
DE19908041A1 (de) * 1999-02-24 2000-08-31 Hoecker Hartwig Kovalent verbrückte Insulindimere
KR100449454B1 (ko) 2000-10-02 2004-09-21 이현철 단일사슬 인슐린 유도체의 유전자를 포함하는 당뇨병치료용 벡터
AU2002248464A1 (en) 2001-02-21 2002-09-12 Medtronic Minimed, Inc. Stabilized insulin formulations
US7105314B2 (en) 2001-04-02 2006-09-12 Novo Nordisk A/S Method for making human insulin precursors
EP2226316B1 (en) 2002-05-30 2016-01-13 The Scripps Research Institute Copper-catalysed ligation of azides and acetylenes
KR100507796B1 (ko) 2003-04-03 2005-08-17 한미약품 주식회사 생체내 반감기가 증가된 ｐｅｇ-생리활성 폴리펩티드 동종이량체 결합체 및 이의 제조방법
WO2005054291A1 (en) 2003-12-03 2005-06-16 Novo Nordisk A/S Single-chain insulin
WO2006045710A2 (en) 2004-10-27 2006-05-04 Novo Nordisk A/S Insulin receptor binding peptides with non-insulin gene activation profiles and uses thereof
US7807619B2 (en) 2004-11-01 2010-10-05 The Regents Of The University Of California Compositions and methods for modification of biomolecules
WO2006097521A1 (en) 2005-03-18 2006-09-21 Novo Nordisk A/S Pegylated single-chain insulin
JP2009527526A (ja) 2006-02-21 2009-07-30 ノボ・ノルデイスク・エー／エス 単鎖インスリンのアナログとその製薬的製剤
WO2007104738A2 (en) 2006-03-13 2007-09-20 Novo Nordisk A/S Acylated single chain insulin
WO2007104734A1 (en) 2006-03-13 2007-09-20 Novo Nordisk A/S Acylated single chain insulin
WO2007104736A2 (en) 2006-03-13 2007-09-20 Novo Nordisk A/S Acylated single chain insulin
WO2007104737A1 (en) 2006-03-13 2007-09-20 Novo Nordisk A/S Acylated single chain insulin
JP5256199B2 (ja) 2006-08-07 2013-08-07 テヴァ バイオファーマシューティカルズ ユーエスエー，インコーポレーティッド アルブミン−インスリン融合タンパク質
WO2008145721A2 (en) * 2007-06-01 2008-12-04 Novo Nordisk A/S N-terminal modification of polypeptides for protection against degradation by aminopeptidases
WO2009099763A1 (en) 2008-01-30 2009-08-13 Indiana University Research And Technology Corporation Ester-based peptide prodrugs
WO2009132129A2 (en) 2008-04-22 2009-10-29 Case Western Reserve University Isoform-specific insulin analogues
TWI394580B (zh) * 2008-04-28 2013-05-01 Halozyme Inc 超快起作用胰島素組成物
RS56632B1 (sr) * 2008-10-17 2018-03-30 Sanofi Aventis Deutschland Kombinacija insulina i glp-1-agonista
AU2009335715B2 (en) 2008-12-19 2016-09-15 Indiana University Research And Technology Corporation Amide-based insulin prodrugs
WO2010080606A1 (en) 2008-12-19 2010-07-15 Indiana University Research And Technology Corporation Insulin analogs
WO2011059895A1 (en) 2009-11-11 2011-05-19 Quest Diagnostics Investments Incorporated Hexa mutations
CA2802485C (en) * 2010-06-16 2019-09-17 Indiana University Research And Technology Corporation Single chain insulin agonists exhibiting high activity at the insulin receptor
US8255297B2 (en) 2010-07-20 2012-08-28 Facebook, Inc. Creation, redemption, and accounting in a virtual currency system
JP2013540771A (ja) * 2010-10-15 2013-11-07 ノヴォ ノルディスク アー／エス 新規ｎ末端修飾インスリン誘導体
EP2771026A4 (en) * 2011-10-27 2015-08-05 Univ Case Western Reserve QUICKLY ULTRA-CONCENTRATED INSULIN ANALOG FORMULATIONS
EP3395358B1 (en) 2012-09-26 2019-11-06 Indiana University Research and Technology Corporation Insulin analog dimers
WO2014141165A1 (en) 2013-03-15 2014-09-18 Universite De Geneve Use of insulin signaling antagonists, optionally in combination of transfection of non-beta cells, for inducing insulin production
AU2014329567B2 (en) * 2013-10-04 2019-07-25 Merck Sharp & Dohme Corp. Glucose-responsive insulin conjugates
WO2015073575A2 (en) * 2013-11-12 2015-05-21 Centre For Probe Development And Commercialization Residualizing linkers and uses thereof
PE20161153A1 (es) 2014-01-20 2016-10-27 Hanmi Pharm Ind Co Ltd Insulina de accion prolongada y uso de la misma
JP6484337B2 (ja) 2014-11-21 2019-03-13 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． インスリン受容体部分アゴニスト

Also Published As

Publication number Publication date
DOP2017000124A (es) 2017-08-15
AU2018211207A1 (en) 2018-08-16
AU2018211208B2 (en) 2020-09-10
KR102101136B1 (ko) 2020-04-14
KR102049647B1 (ko) 2019-11-29
TW201625673A (zh) 2016-07-16
MX2017006651A (es) 2017-08-21
AU2015349890B2 (en) 2018-08-30
AU2018211207B2 (en) 2020-04-09
AU2015349890A1 (en) 2017-06-01
JP6931033B2 (ja) 2021-09-01
BR122024000898A2 (pt) 2024-02-27
JP2018501203A (ja) 2018-01-18
IL252257A0 (en) 2017-07-31
JP2019014735A (ja) 2019-01-31
MX2020014121A (es) 2021-03-25
CL2019001143A1 (es) 2019-07-19
NI201700060A (es) 2017-07-18
PH12017500935A1 (en) 2017-11-27
WO2016081670A3 (en) 2016-08-04
US20180291078A1 (en) 2018-10-11
US10017556B2 (en) 2018-07-10
EA036714B1 (ru) 2020-12-10
CA3014641C (en) 2020-08-18
EP3660041B1 (en) 2023-04-19
EP3666792A3 (en) 2020-07-29
BR122024000903A2 (pt) 2024-02-27
SG11201704064TA (en) 2017-06-29
AR102712A1 (es) 2017-03-22
JP2019014734A (ja) 2019-01-31
JP6703068B2 (ja) 2020-06-03
EP3660040A3 (en) 2020-07-29
SG10201809457YA (en) 2018-11-29
EA201791117A1 (ru) 2017-11-30
JP2020097572A (ja) 2020-06-25
ES2946247T3 (es) 2023-07-14
SV2017005445A (es) 2018-04-04
CL2019001144A1 (es) 2019-07-19
BR112017010481A8 (pt) 2023-04-11
AU2018211208A1 (en) 2018-08-16
CA3014641A1 (en) 2016-05-26
CA2966765A1 (en) 2016-05-26
WO2016081670A2 (en) 2016-05-26
EP3666792A2 (en) 2020-06-17
US10800827B2 (en) 2020-10-13
EP3660040A2 (en) 2020-06-03
GT201700104A (es) 2018-11-27
CO2017004976A2 (es) 2017-10-10
JP6943825B2 (ja) 2021-10-06
US10183981B2 (en) 2019-01-22
CL2017001288A1 (es) 2017-12-15
KR20190069622A (ko) 2019-06-19
CN112494656A (zh) 2021-03-16
SG10201809427SA (en) 2018-11-29
CA2966765C (en) 2020-04-14
CN112494656B (zh) 2024-01-30
CR20170208A (es) 2017-07-17
ZA201703238B (en) 2018-05-30
US20170107268A1 (en) 2017-04-20
US20190092833A1 (en) 2019-03-28
CN108064173B (zh) 2021-05-18
JP6484337B2 (ja) 2019-03-13
EP3221343A2 (en) 2017-09-27
EP3221343B1 (en) 2020-09-16
PE20170957A1 (es) 2017-07-13
CN108064173A (zh) 2018-05-22
TN2017000178A1 (en) 2018-10-19
EP3660041A1 (en) 2020-06-03
JP2019011357A (ja) 2019-01-24
KR20170084300A (ko) 2017-07-19
MX2020014120A (es) 2021-03-25
BR112017010481A2 (pt) 2018-04-03
US20170355743A1 (en) 2017-12-14

Similar Documents

Publication Publication Date Title
SG10201809428UA (en) Insulin receptor partial agonists
PH12020550781A1 (en) Anti-jagged1 antibodies and methods of use
PH12018500711A1 (en) Anti-pd1 antibodies and methods of use
PH12017500877A1 (en) ANTI-CD79b ANTIBODIES AND METHODS OF USE
MX2017005920A (es) Anticuerpos anti-tim3 y metodos de uso.
MY193723A (en) Combination therapy of tumor-targeted il-2 variant immunocytokines and antibodies against human pd-l1
MX2017003022A (es) Anticuerpos anti-cll-1 e inmunoconjugados.
MX2020004073A (es) Procesos de siembra en serie y usos de los mismos.
MX2016015162A (es) Anticuerpos anti - gpc3 e inmunoconjugados.
MX2020012893A (es) Formulaciones de proteinas.
MX2016016233A (es) Anticuerpos anti-lgr5 y sus usos.
MX2019011297A (es) Complejo de analogo de insulina con afinidad reducida por el receptor de insulina y uso del mismo.
MX2016015280A (es) Anticuerpos anti-bromodesoxiuridina(brdu) y metodos de uso.
MY167350A (en) Fat-and-oil composition and chocolate
NZ719451A (en) Glucagon analog for treatment of severe hypoglycemia
MX2017003949A (es) Derivados peptidicos novedosos y sus usos.
EA201991576A1 (ru) Частичные агонисты инсулинового рецептора
NZ744340A (en) Anti-jagged1 antibodies and methods of use
UA99992U (ru) 2-оксо-4-фенил-5-циано-1,2,3,4-тетрагидропиридин-6-тиолат n-метилморфолиния